SLU-PP-332

SLU-PP-332 may provide modest increases in mitochondrial oxidative capacity and treadmill endurance for highly controlled self-experiments, yet the evidence is limited to rodent models and human safety data are absent. The synthetic pan-ERR agonist boosted mouse exercise performance after eight days of daily injection, an effect that depended on ERR alpha activation and was linked to enhanced fatty-acid oxidation Billon 2023. Follow-up mouse studies reported improvements in obesity-related metabolic markers, including lower fasting glucose and reduced hepatic fat, when SLU-PP-332 was administered over several weeks Billon 2024. Cardiovascular mouse models also showed better ejection fraction and reduced fibrosis after treatment Xu 2024. Because no human pharmacokinetic or dose-finding trials exist, any benefit in people remains speculative and must be weighed against unknown adverse-event risk.

✅ Best for: Advanced biohackers with medical supervision who are explicitly studying exercise-mimetic pharmacology, understand the corrected evidence base, and accept that SLU-PP-332 is preclinical only. The strongest fit is a researcher or unusually risk-tolerant self-experimenter who has already optimized training, nutrition, sleep, creatine, cardiometabolic labs, and body composition fundamentals. It may also be worth following academically if you care about ERR pharmacology, mitochondrial medicine, obesity-drug development, heart-failure metabolism, or doping-control evolution.

❌ Avoid if: You want human clinical evidence before exposure; you take medications; you have cardiovascular disease, active or historical cancer, liver or kidney disease, psychiatric instability, or fertility goals; you are pregnant, breastfeeding, under 25, or competing in tested sport. Avoid SLU-PP-332 if you cannot independently verify product identity and purity, or if you are using it as a substitute for exercise. The audit found no FDA approval, no Cochrane review, no human trial, and no medical-society endorsement. Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.